Meridian Bioscience, Inc. (NASDAQ:VIVO) is in the list of top stocks to avoid today as the company shares are trading 4.83% or 0.57 points down from last closing price of $11.81, reaching $11.24 at last check. The VIVO share price has dropped in 3 of the last 5 days and is up 2.61% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -48,176 shares, and in total 104024 shares valued at $1.169 million were seen changing hands compared with 152200 shares valued at $1.797 million recorded at the previous session. You should take into consideration that a falling volume on lower prices shows the bearish trend but this is an early indication which means that the VIVO stock is near its bottom.
Meridian Bioscience, Inc. (VIVO) shares have notched a 3-month gain of about 2.61%, but has still tumbled -31.97% year to date. By comparison, the stock sank -23.56% over the past 12 months, while it slipped -0.17% over the 1 month. The company’s market cap is around $511.96M, with its short interest ratio standing at 7.79%.
In the current trading session for VIVO, the stock witnessed two major price actions, it rose to a high of $11.66 and was down as much as $11.2 at one point. The high recorded is very low when compared to their 52-week high which is $10.77. The 52-week high is now at -43.37 distance from current price. Their recent low of $19.84 represents a 4.32% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for VIVO is $10.67, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
The stock of Meridian Bioscience, Inc. earned $0.59 per share in the trailing 12 months and has a P/E ratio of 19.05. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 33.28 and lower compared to the sector’s average of 33.85. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. VIVO also has P/S multiple of 2.4. This is smaller versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 6.58x.
The company recorded an interesting insider purchase transaction by the Director on May 22, 2019. A Securities and Exchanges Commission filings show that John Mccune Jr. Rice bought a total of 2,000 VIVO shares that day for a sum of around $22,520. Meridian Bioscience, Inc. (VIVO) insiders have acquired 35,188 shares in the stock within the past three months. In total, individual insiders traded 38,376 shares in the business, which makes up 20.435% of 187,797 shares that were traded over a year. In the past 12 months, insiders have purchased 137,605 shares while the seller parted with 50,192 shares.
VIVO‘s last price was down -24.22% as compared to the average trading price of 50 days recorded at $14.83 while enlarging the period to 200 trading days, the average closing price was $11.55. At present, there are 43.35 million in the total number of common shares owned by the public and among those 42.14 million shares have been available to trade. The percentage of shares being held by the company management was 0.3% while institutions stake was 94.7%. The company has generated positive returns on equity over the last 12 months (14.4%). It managed to keep its gross profit margin at 59.7% over the past 12 months.
When assessing the full upside of the VIVO stock, there is another set of technicals that should be looked into and considered. Its -3.09% decline from moving average of $11.6 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 0.3 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of Meridian Bioscience, Inc. — 0 analysts rate the stock as a buy with another 0 rating it strong buy. There are 2 analysts who maintain a hold rating for the stock, with 1 giving it a sell rating. Analysts arrived at a 12-month price target of $11.3333 on shares of Meridian Bioscience, Inc. (NASDAQ:VIVO), which corresponds to 0.83% upside potential than its current market price of $11.24 and implies potential despite the recent drop in the price. However, their current target price has climbed from $8.9333 a month ago and is down handily from the consensus target of $11.3333 a quarter ago.
In the last five years, the EPS of the company has been roughly -10.7%. Though the percentage looks disappointing, extra tailwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will increase annually by 17%. The revenue of the company has risen at an average annualized rate of about 2.5 over the last five years. The company recently recorded a drop of -11.2%, but this figure is rather unattractive.
Let’s briefly check the hedge fund interest towards VIVO stock. Meeder Asset Management Inc. added position in the company after it grew 710.6% or 1,552 shares of its common stock. The hedge fund now owns 12,580 shares worth $141,399, SEC documents show. Teton Advisors Inc. cut assets in the stock as 134065.9 shares have been sold, reducing its stake by -9% to 122,000 shares which are currently valued at $1,371,280. In addition, Gabelli Funds LLC recently reported that it now owns 125,500 shares making a total of $1,410,620 based on the recent price. This refelects a change of -25.7% in their ownership.